You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIron Dextran
Accession NumberDB00893  (APRD01053)
TypeSmall Molecule
GroupsApproved
Description

Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.

Structure
Thumb
Synonyms
Dexferrum
Dextran iron
External Identifiers
  • UNII-95HR524N2M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dexferruminjection, solution50 mg/mLintravenousAmerican Regent, Inc.1998-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dexferruminjection, solution50 mg/mLintravenousAmerican Regent, Inc.1996-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Infedinjection, solution50 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Infedinjection50 mg/mLintramuscular; intravenousActavis Pharma, Inc.1974-04-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
CosmoFerB. Braun
FeosolGlaxoSmithKline
ImferonSanofi-Aventis
ProferdexNew River Pharmaceuticals Inc.
Brand mixtures
NameLabellerIngredients
BiferarxMEDA Pharmaceuticals
Prefera Ob Plus DHAAlaven Pharmaceutical LLC
PreferaobAlaven Pharmaceutical LLC
Preferaob Plus DHAAlaven Pharmaceutical LLC
Purevit Dualfe PlusPure Tek Corporation
Se-tan DHASeton Pharmaceuticals
Se-tan PlusSeton Pharmaceuticals
SaltsNot Available
Categories
UNII95HR524N2M
CAS number9004-66-4
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationFor treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Also used to replenish body iron stores in Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving erythropoietin and in Hemodialysis Dependent (HDD-CKD) and Peritoneal Dialysis Dependent (PDD-CKD) - Chronic Kidney Disease patients receiving an erythropoietin.
PharmacodynamicsIron dextran is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. It is for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Iron is essential to the formation of hemoglobin and to the function and formation of other heme and nonheme compounds. Untreated depletion of iron stores leads to iron-deficient erythropoiesis and, in turn, to iron deficiency anemia.
Mechanism of actionAfter iron dextran is injected, the circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.
AbsorptionThe major portion of intramuscular injections of iron dextran is absorbed within 72 hours; most of the remaining iron is absorbed over the ensuing 3 to 4 weeks.
Volume of distributionNot Available
Protein binding100% (after release from dextran)
Metabolism

Dextran, a polyglucose, is either metabolized or excreted.

Route of eliminationDextran, a polyglucose, is either metabolized or excreted.
Half life5 hours (some indications that it can be as long as 10 hours)
ClearanceNot Available
ToxicityLD50 = 500 mg/kg (mouse, IV). Dosages of iron dextran in excess of the requirements for restoration of hemoglobin and replenishment of iron stores may lead to hemosiderosis. Cases of severe, sometimes fatal, allergic reactions (loss of consciousness, collapse, difficulty breathing, hives, swelling, or convulsions) and severe low blood pressure (hypotension) have been reported with the use of iron dextran.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Luitpold pharmaceuticals inc
  • Watson laboratories inc
  • Sanofi aventis us llc
  • New river pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Injection, solutionintravenous50 mg/mL
Injectionintramuscular; intravenous50 mg/mL
Injection, solutionintramuscular; intravenous50 mg/mL
Capsuleoral
Capsule, gelatin coatedoral
Prices
Unit descriptionCostUnit
Iron dextran comp 100 mg/2 ml38.08USD ml
Dexferrum 100 mg/2 ml vial21.6USD ml
Dexferrum 50 mg/ml vial21.6USD ml
Dexiron 50 mg/ml15.66USD ml
Infufer 50 mg/ml15.53USD ml
Infed 100 mg/2 ml vial14.44USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States56246681995-09-292015-09-29
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
References
Synthesis Reference

William T. Monte, Laurie Scaggs, “Process for making crystalline iron dextran.” U.S. Patent US5756715, issued 1905.

US5756715
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (45.1 KB)
Interactions
Drug Interactions
Drug
AlendronateThe serum concentration of Alendronate can be decreased when it is combined with Iron Dextran.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron Dextran.
BiotinBiotin can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Iron Dextran.
CarbidopaThe serum concentration of Carbidopa can be decreased when it is combined with Iron Dextran.
CefdinirThe serum concentration of Cefdinir can be decreased when it is combined with Iron Dextran.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron Dextran.
CimetidineCimetidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Iron Dextran.
ClodronateThe serum concentration of Clodronate can be decreased when it is combined with Iron Dextran.
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Iron Dextran.
DemeclocyclineDemeclocycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
DimercaprolDimercaprol may increase the nephrotoxic activities of Iron Dextran.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Iron Dextran.
DoxycyclineDoxycycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Iron Dextran.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Iron Dextran.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Iron Dextran.
EntacaponeThe serum concentration of Entacapone can be decreased when it is combined with Iron Dextran.
EsomeprazoleEsomeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
FamotidineFamotidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron Dextran.
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Iron Dextran.
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Iron Dextran.
LansoprazoleLansoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
LevodopaThe serum concentration of Levodopa can be decreased when it is combined with Iron Dextran.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Iron Dextran.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Iron Dextran.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Iron Dextran.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethyldopaThe serum concentration of Methyldopa can be decreased when it is combined with Iron Dextran.
MinocyclineMinocycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron Dextran.
MoxifloxacinThe serum concentration of Moxifloxacin can be decreased when it is combined with Iron Dextran.
NizatidineNizatidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Iron Dextran.
OfloxacinThe serum concentration of Ofloxacin can be decreased when it is combined with Iron Dextran.
OmeprazoleOmeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
PancrelipasePancrelipase can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
PantoprazolePantoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
PenicillamineIron Dextran can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Iron Dextran.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron Dextran.
RabeprazoleRabeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Iron Dextran.
RanitidineRanitidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Iron Dextran.
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
TetracyclineTetracycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
TiludronateThe serum concentration of Tiludronate can be decreased when it is combined with Iron Dextran.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Iron Dextran.
TriethylenetetramineThe serum concentration of Iron Dextran can be decreased when it is combined with Triethylenetetramine.
Food InteractionsNot Available

Targets

1. Hemoglobin subunit beta

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: activator

Components

Name UniProt ID Details
Hemoglobin subunit beta P68871 Details

References:

  1. Zaric J, Lazic D, Markovic S, Glisin V, Ivanovic Z, Milenkovic P, Popovic Z: Alpha- and beta-globins of the anemic Belgrade laboratory rat. II. The effect of hemin and iron-dextran treatment. Hemoglobin. 1998 May;22(3):231-44. Pubmed
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Hemoglobin subunit alpha

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: activator

Components

Name UniProt ID Details
Hemoglobin subunit alpha P69905 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Ferritin heavy chain

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: other

Components

Name UniProt ID Details
Ferritin heavy chain P02794 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Ferritin light chain

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: other

Components

Name UniProt ID Details
Ferritin light chain P02792 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

Carriers

1. Serotransferrin

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Serotransferrin P02787 Details

References:

  1. Macdougall IC: Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999 Mar;69:S61-6. Pubmed
  2. Salahudeen AK, Oliver B, Bower JD, Roberts LJ 2nd: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 2001 Oct;60(4):1525-31. Pubmed
  3. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG: Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007 Mar;27(3):343-50. Pubmed
  4. Jacobs JC, Alexander NM: Colorimetry and constant-potential coulometry determinations of transferrin-bound iron, total iron-binding capacity, and total iron in serum containing iron-dextran, with use of sodium dithionite and alumina columns. Clin Chem. 1990 Oct;36(10):1803-7. Pubmed
  5. Speyer BE, Doney VJ, Fielding J: Transfer of iron from Ferastral and other organic complexes to transferrin as measured by reticulocyte uptake. Scand J Haematol Suppl. 1977;32:215-21. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 11, 2013 08:55